Two features of SGLT2i are of particular interest: (i) a mechanism of action not linked to insulin secretion, which makes the detrimental occurrence of hypoglycemia less likely compared to other anti-diabetic drug classes; and (ii) cardiovascular and renal protective effects independent of its’ glycemic control and noted early after initiation of the therapy, suggesting mechanisms of action beyond blood glucose lowering [1,2]. This evidence concerns the gene INS and Hypoglycemia.